ReviewBritish journal of pharmacology2018
Circadian modulation of neuroplasticity by melatonin: a target in the treatment of depression.
Review in British journal of pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 98 citations in OpenAlex.
- The effect of acupuncture on depression and its correlation with metabolic alterations: A randomized controlled trial.Medicine · 2020Trial
- Trial
- Occupational circadian disruption and brain structure: evidence from normative developmental brain lifespan trajectories.Brain structure & function · 2026Article
- Detailed Review of Melatonin and its Role in Managing the Symptoms of Depression.Current molecular medicine · 2026Review
- Sex-Dependent Effects of Circadian Rhythm Disruptions on Novel Object Recognition Memory, Locomotion, Pain Threshold, Rearing Behavior, and BDNF and GSK-3β Hippocampal Levels in Rats.Behavioural neurology · 2026Article
- Article
- Article
- Exploring the association between melatonin and nicotine dependence (Review).International journal of molecular medicine · 2024Review
- Recent Progress in Biosensors for Depression Monitoring-Advancing Personalized Treatment.Biosensors · 2024Review
- Article
- Associations of exposure to volatile organic compounds with sleep health and potential mediators: analysis of NHANES data.Frontiers in public health · 2024Article
- Exploring the potential use of melatonin as a modulator of tramadol-induced rewarding effects in rats.Frontiers in pharmacology · 2024Article
- Brain structural correlates of subjective sleepiness and insomnia symptoms in shift workers.Frontiers in neuroscience · 2024Article
- Melatonin in animal husbandry: functions and applications.Frontiers in veterinary science · 2024Review
- Circadian Rhythms and Sleep Disorders Associated to Major Depressive Disorder: Pathophysiology and Therapeutic Opportunities.CNS & neurological disorders drug targets · 2024Review
- A multicenter, randomized controlled study on the efficacy of agomelatine in ameliorating anhedonia, reduced motivation, and circadian rhythm disruptions in patients with major depressive disorder (MDD).Annals of general psychiatry · 2023Article
- ASMT determines gut microbiota and increases neurobehavioral adaptability to exercise in female mice.Communications biology · 2023Article
- Sleep-associated insulin resistance promotes neurodegeneration.Molecular biology reports · 2023Review
- Design, synthesis, molecular docking and DFT studies on novel melatonin and isatin based azole derivatives.RSC advances · 2023Article
- Are sleep disturbances a cause or consequence of autism spectrum disorder?Psychiatry and clinical neurosciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
Abstract
Mood disorders are a spectrum of neuropsychiatric disorders characterized by changes in the emotional state. In particular, major depressive disorder is expected to have a worldwide prevalence of 20% in 2020, representing a huge socio-economic burden. Currently used antidepressant drugs have poor efficacy with only 30% of the patients in remission after the first line of treatment. Importantly, mood disorder patients present uncoupling of circadian rhythms. In this regard, melatonin (5-methoxy-N-acetyltryptamine), an indolamine synthesized by the pineal gland during the night, contributes to synchronization of body rhythms with the environmental light/dark cycle. In this review, we describe evidence supporting antidepressant-like actions of melatonin related to the circadian modulation of neuroplastic changes in the hippocampus. We also present evidence for the role of melatonin receptors and their signalling pathways underlying modulatory effects in neuroplasticity. Finally, we briefly discuss the detrimental consequences of circadian disruption on neuroplasticity and mood disorders, due to the modern human lifestyle. Together, data suggest that melatonin's stimulation of neurogenesis and neuronal differentiation is beneficial to patients with mood disorders. LINKED ARTICLES: This article is part of a themed section on Recent Developments in Research of Melatonin and its Potential Therapeutic Applications. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.16/issuetoc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.